Hanmi Pharm (128940 KS): Flagship Drugs Boost 3Q25 Result Amid Obesity Pipeline Progress
Hanmi Pharm reports mixed 3Q25 performance with flat topline and mid-single digit growth in operating profit. Expectations are rising on...
572 Views
Hanmi Pharm (128940 KS): Domestic Business Fuels 2Q Result; New Launches to Drive Near-Term Growth
Hanmi Pharm sees 6% YoY revenue growth in domestic business in 2Q25. In 3Q25, the company has launched Prolia biosimilar and next-generation low...
375 Views
Hanmi Pharm (128940 KS): Export Drives 1Q25 Performance; China Business Is Recovering
Hanmi Pharm recorded 47% YoY jump in export revenue to KRW68B in 1Q25. Beijing Hanmi shows recovery with 29% QoQ sales jump . Next-gen...
450 Views
Hanmi Pharm (128940 KS): Corporate Value Enhancement Plan Targets W5 Trillion Revenue by 2033
Hanmi Pharm aims for robust revenue growth, targeting KRW2.3T in 2027 and KRW5T by 2033. Operating profit margin is expected to improve from 14.4%...
315 Views
2023 in Rear Mirror View: Top Performers From My Global Healthcare Coverage Universe
Despite ongoing recovery and fading effect of the COVID-19, healthcare companies had varying performances in 2023. From my coverage, the top...
762 Views